-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Quest Diagnostics, Lowers Price Target to $175

Benzinga·07/18/2025 18:22:55
Listen to the news
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and lowers the price target from $176 to $175.